Cargando…

Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer

Acquired resistance to chemotherapy is a major limitation in clinical treatment for breast cancer. Accumulating evidence from in vitro, in vivo and clinical studies suggest that acquired chemoresistance is progressive, multifactorial and involve genetic and epigenetic aberrations. Among various mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponnusamy, Logeswari, Mahalingaiah, Prathap Kumar S., Chang, Yu-Wei, Singh, Kamaleshwar P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992622/
https://www.ncbi.nlm.nih.gov/pubmed/35582717
http://dx.doi.org/10.20517/cdr.2018.11
_version_ 1784683766910812160
author Ponnusamy, Logeswari
Mahalingaiah, Prathap Kumar S.
Chang, Yu-Wei
Singh, Kamaleshwar P.
author_facet Ponnusamy, Logeswari
Mahalingaiah, Prathap Kumar S.
Chang, Yu-Wei
Singh, Kamaleshwar P.
author_sort Ponnusamy, Logeswari
collection PubMed
description Acquired resistance to chemotherapy is a major limitation in clinical treatment for breast cancer. Accumulating evidence from in vitro, in vivo and clinical studies suggest that acquired chemoresistance is progressive, multifactorial and involve genetic and epigenetic aberrations. Among various mechanisms that contribute to chemoresistance, cellular reprogramming has extensively been implicated in breast cancer resistance lately. Cellular reprogramming events such as acquisition of epithelial to mesenchymal transition (EMT) and cancer stemness (CSCs) not only provide cancer cells with reversible phenotypic plasticity and survival advantage against cytotoxicity but also leads to aggressiveness, metastasis, clinical resistance, tumor recurrence and poor survival. The transient and reversible nature of cellular reprogramming processes and their controlled interaction with epigenetic regulatory complexes strongly support the involvement of dynamic epigenetic regulatory network in governing the cellular reprogramming and associated acquired chemoresistance. Further, epigenetic modulations are also gaining interest as promising interventions addressing the cancer cell reprogramming machinery to overcome acquired chemoresistance. This review discusses the previous reports and our recent findings that lead to current understanding of epigenetic dysregulation dictating the cellular reprogramming processes such as acquisition of EMT and CSCs phenotype and how they co-ordinate to establish acquired drug resistance in breast cancer.
format Online
Article
Text
id pubmed-8992622
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-89926222022-05-16 Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer Ponnusamy, Logeswari Mahalingaiah, Prathap Kumar S. Chang, Yu-Wei Singh, Kamaleshwar P. Cancer Drug Resist Review Acquired resistance to chemotherapy is a major limitation in clinical treatment for breast cancer. Accumulating evidence from in vitro, in vivo and clinical studies suggest that acquired chemoresistance is progressive, multifactorial and involve genetic and epigenetic aberrations. Among various mechanisms that contribute to chemoresistance, cellular reprogramming has extensively been implicated in breast cancer resistance lately. Cellular reprogramming events such as acquisition of epithelial to mesenchymal transition (EMT) and cancer stemness (CSCs) not only provide cancer cells with reversible phenotypic plasticity and survival advantage against cytotoxicity but also leads to aggressiveness, metastasis, clinical resistance, tumor recurrence and poor survival. The transient and reversible nature of cellular reprogramming processes and their controlled interaction with epigenetic regulatory complexes strongly support the involvement of dynamic epigenetic regulatory network in governing the cellular reprogramming and associated acquired chemoresistance. Further, epigenetic modulations are also gaining interest as promising interventions addressing the cancer cell reprogramming machinery to overcome acquired chemoresistance. This review discusses the previous reports and our recent findings that lead to current understanding of epigenetic dysregulation dictating the cellular reprogramming processes such as acquisition of EMT and CSCs phenotype and how they co-ordinate to establish acquired drug resistance in breast cancer. OAE Publishing Inc. 2019-06-19 /pmc/articles/PMC8992622/ /pubmed/35582717 http://dx.doi.org/10.20517/cdr.2018.11 Text en © The Author(s) 2019. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Ponnusamy, Logeswari
Mahalingaiah, Prathap Kumar S.
Chang, Yu-Wei
Singh, Kamaleshwar P.
Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
title Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
title_full Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
title_fullStr Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
title_full_unstemmed Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
title_short Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
title_sort role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992622/
https://www.ncbi.nlm.nih.gov/pubmed/35582717
http://dx.doi.org/10.20517/cdr.2018.11
work_keys_str_mv AT ponnusamylogeswari roleofcellularreprogrammingandepigeneticdysregulationinacquiredchemoresistanceinbreastcancer
AT mahalingaiahprathapkumars roleofcellularreprogrammingandepigeneticdysregulationinacquiredchemoresistanceinbreastcancer
AT changyuwei roleofcellularreprogrammingandepigeneticdysregulationinacquiredchemoresistanceinbreastcancer
AT singhkamaleshwarp roleofcellularreprogrammingandepigeneticdysregulationinacquiredchemoresistanceinbreastcancer